Welcome to our dedicated page for American Well news (Ticker: AMWL), a resource for investors and traders seeking the latest updates and insights on American Well stock.
About American Well Corporation (Amwell)
American Well Corporation (NYSE: AMWL), widely known as Amwell, is a leading hybrid care enablement platform revolutionizing the healthcare industry by integrating technology to deliver accessible, affordable, and high-quality care. Headquartered in Boston, Amwell operates at the intersection of healthcare and technology, empowering providers, payers, patients, and innovators to seamlessly deliver care across the entire healthcare continuum. The company's platform supports diverse healthcare needs, including urgent care, chronic care management, behavioral health, post-acute care, and healthy living initiatives.
Core Offerings and Business Model
Amwell provides a single, comprehensive platform that combines virtual and in-person care to create a unified healthcare experience. Its offerings include on-demand and scheduled consultations, virtual primary care, musculoskeletal care, dermatology, and chronic disease management. The platform integrates third-party digital health solutions, such as Hello Heart for cardiovascular health and Vida Health for cardiometabolic care, enabling health systems and insurers to offer tailored, cost-effective, and outcome-driven programs to their members.
The company generates revenue through partnerships with over 50 health plans, representing more than 100 million covered lives, and collaborates with leading health systems comprising thousands of hospitals. Its SaaS-based model ensures scalability and adaptability, catering to the evolving needs of healthcare organizations. Amwell's robust ecosystem also includes its affiliated clinical partner, Amwell Medical Group, which delivers behavioral health and therapy services.
Industry Context and Market Position
Operating in the rapidly growing telehealth and digital health industry, Amwell is strategically positioned to address the global shift towards hybrid care delivery. With nearly two decades of experience, the company has established itself as a trusted partner for some of the largest and most sophisticated healthcare organizations worldwide. Its proprietary platform, Amwell Converge™, integrates advanced technologies to enhance care coordination, data exchange, and patient engagement, ensuring efficient and personalized healthcare delivery.
Amwell differentiates itself from competitors like Teladoc Health through its focus on a unified, interoperable platform that supports a wide range of clinical programs. By fostering partnerships with innovative digital health providers, Amwell continuously expands its portfolio, addressing critical health challenges such as obesity, diabetes, and cardiovascular diseases. This collaborative approach positions the company as a key enabler of value-based care models.
Challenges and Strategic Focus
As a pioneer in digital healthcare, Amwell faces challenges such as ensuring data security, navigating regulatory complexities, and driving adoption across diverse patient populations. The company addresses these challenges by investing in robust cybersecurity measures, aligning with industry standards, and leveraging its extensive network of partners to enhance accessibility and affordability.
Amwell's strategic focus on hybrid care delivery underscores its commitment to transforming healthcare. By integrating virtual and in-person services, the company aims to bridge care gaps, improve clinical outcomes, and reduce costs for patients and healthcare organizations alike. This approach aligns with industry trends emphasizing whole-person care and personalized health solutions.
Conclusion
American Well Corporation is at the forefront of digital healthcare innovation, enabling its clients to deliver seamless, patient-centric care. With its comprehensive platform, strategic partnerships, and commitment to hybrid care, Amwell is well-positioned to shape the future of healthcare delivery. Its emphasis on scalability, interoperability, and clinical excellence ensures it remains a valuable partner for health systems, insurers, and employers seeking to navigate the evolving healthcare landscape.
Amwell (NYSE: AMWL) has appointed Susan Worthy as Chief Marketing Officer. With over 25 years in healthcare marketing, her role involves leading Amwell’s overall marketing strategy to enhance market position and shareholder value. Worthy previously led marketing at Optum, and her expertise is expected to drive growth during a transformative period for the company. She succeeds Mary Modahl, who retires after over a decade at Amwell. The company aims to improve healthcare access via technology and support over 80 million lives through its telehealth platform.
Amwell (NYSE: AMWL), a leader in telehealth, announced participation in key investor conferences. On May 11, 2022, Dr. Ido Schoenberg, CEO, and CFO Bob Shepardson will present at the BofA Healthcare Conference in Las Vegas. They will also participate in the RBC Capital Markets Healthcare Conference in New York City on May 17, 2022, at 2:05 p.m. ET, and at the Needham Virtual Tech and Media Conference on May 19, 2022, at 10:15 a.m. ET. Audio webcasts will be available on their investor relations website.
Amwell (NYSE: AMWL) has expanded its virtual specialty care offerings, introducing Musculoskeletal (MSK) and Dermatology programs. These initiatives cater to healthcare challenges affecting approximately 50% of U.S. adults, focusing on costly musculoskeletal conditions and the shortage of dermatologists. The MSK program aims to improve access to physical therapy and enhance treatment adherence through digital tools. Meanwhile, the Dermatology program provides quick access to care, reducing the average wait time for in-person visits from 35 days to 24 hours for diagnoses.
Amwell (NYSE: AMWL), a leader in telehealth, will report its first-quarter operating results for the period ending March 31, 2022, on May 9, 2022. Following the earnings release, the management team will host a live conference call at 5:00 p.m. ET to discuss results and provide a business update. Investors can access the webcast on the company's website and call in using provided numbers. Amwell connects providers and patients to enhance healthcare delivery, supporting over 80 million lives through partnerships with 2,000 hospitals and 55 health plans.
Amwell (NYSE: AMWL) has announced a shortened earnout period for its acquisition of Conversa Health, which was purchased in August 2021. This strategic move is expected to enhance integration and support new product development, cross-selling opportunities, and operational efficiencies. In coordination, Amwell issued 1,020,964 shares of Class A common stock to Conversa's former stockholders. Amwell's CEO emphasized the seamless integration as a key driver for improved care delivery and innovative healthcare solutions.
Amwell (NYSE: AMWL), a leader in telehealth, announced participation in upcoming investor conferences.
Key events include Cowen’s 42nd Annual Health Care Conference on March 8, 2022, and Keybanc’s Virtual Healthcare Conference on March 22, 2022. Executives Ido Schoenberg, Roy Schoenberg, and Robert Shepardson will represent the company.
Audio webcasts will be accessible on their investor relations website.
Amwell aims to transform healthcare through a comprehensive digital platform, serving over 80 million lives across 55 health plans.
Amwell (NYSE: AMWL) reported strong fourth quarter and full year results for 2021, with total revenue of $252.8 million and gross margins of 41%. The company achieved 1.5 million active visits in Q4, up from 1.4 million in Q3. Subscription revenue rose to $30.1 million, a significant increase from last year. Despite a net loss of ($47.9 million) in Q4, the company aims for revenue growth between $275 million and $285 million for 2022. The increased active providers reached approximately 91,000 indicates positive traction on their Converge platform.
Amwell (NYSE: AMWL), a leader in telehealth, will report its fourth quarter and full year results for the period ended December 31, 2021, on February 24, 2022. The management team will conduct a live conference call and webcast at 5:00 p.m. ET to discuss the results and provide a business update. Interested parties can access the webcast via the Company's Investors website or through a dedicated phone line. Amwell connects providers and patients, covering over 80 million lives and offering a comprehensive telehealth platform for various healthcare needs.
Amwell reported $62.2 million in third-quarter revenue, a slight decrease from $62.6 million a year prior, with gross margins improving to 43.5% compared to 32.7% last year. The company saw an increase in total active providers to approximately 80,000 from 71,000 last quarter, and total visits rose to 1.4 million. The adjusted EBITDA loss was narrowed to ($31.5 million), down from ($26.2 million) year-over-year. Amwell adjusted its financial outlook for revenue to a range of $246 million to $253 million due to COVID-Delta impacts.
Amwell (NYSE: AMWL), a leader in telehealth, will report its third-quarter operating results for the period ending September 30, 2021, on November 10, 2021. Following the release, Amwell's management will host a live conference call and webcast at 5:00 p.m. ET to discuss the results and provide a business update. Interested parties can access the live audio via the Company's website or by calling designated numbers. Amwell connects over 80 million lives through its telehealth platform, offering comprehensive healthcare solutions.
FAQ
What is the current stock price of American Well (AMWL)?
What is the market cap of American Well (AMWL)?
What does American Well Corporation (Amwell) do?
How does Amwell generate revenue?
What makes Amwell different from competitors like Teladoc Health?
What are Amwell's key focus areas?
Who are Amwell's primary clients?
What challenges does Amwell face in its industry?
What is Amwell's approach to hybrid care delivery?
How does Amwell integrate third-party solutions into its platform?
What is Amwell Converge™?
What is Amwell's role in value-based care models?
